Mark Hilz - Heart Test Secretary COO
| HSCSW Stock | USD 0.03 0.00 0.00% |
COO
Mark Hilz is Secretary COO of Heart Test Laboratories
| Age | 65 |
| Address | 550 Reserve Street, Southlake, TX, United States, 76092 |
| Phone | 682-237-7781 |
| Web | https://heartsciences.com |
Mark Hilz Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Hilz against Heart Test stock is an integral part of due diligence when investing in Heart Test. Mark Hilz insider activity provides valuable insight into whether Heart Test is net buyers or sellers over its current business cycle. Note, Heart Test insiders must abide by specific rules, including filing SEC forms every time they buy or sell Heart Test'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Hilz over three months ago Disposition of 3788 shares by Mark Hilz of Heart Test at 12.21 subject to Rule 16b-3 |
Heart Test Management Efficiency
The company has return on total asset (ROA) of (0.8169) % which means that it has lost $0.8169 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (2.6929) %, meaning that it generated substantial loss on money invested by shareholders. Heart Test's management efficiency ratios could be used to measure how well Heart Test manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.88 in 2024. Return On Capital Employed is likely to drop to -0.85 in 2024. At this time, Heart Test's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 2.3 M in 2024, whereas Intangible Assets are likely to drop slightly above 1.3 M in 2024.Heart Test Laboratories has accumulated 1.04 M in total debt. Heart Test Laboratories has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about Heart Test's use of debt, we should always consider it together with its cash and equity.
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company was incorporated in 2007 and is headquartered in Southlake, Texas. Heart Test operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. Heart Test Laboratories (HSCSW) is traded on NASDAQ Exchange in USA. It is located in 550 Reserve Street, Southlake, TX, United States, 76092 and employs 15 people. Heart Test is listed under Health Care Equipment & Supplies category by Fama And French industry classification. Management Performance
| Return On Equity | -2.69 | ||||
| Return On Asset | -0.82 |
Heart Test Laboratories Management Team
Elected by the shareholders, the Heart Test's board of directors comprises two types of representatives: Heart Test inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Heart. The board's role is to monitor Heart Test's management team and ensure that shareholders' interests are well served. Heart Test's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Heart Test's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Danielle Watson, CFO Treasurer | ||
| Andrew Simpson, President CEO | ||
| Mark Hilz, Secretary COO |
Heart Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Heart Test a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.69 | ||||
| Return On Asset | -0.82 | ||||
| Operating Margin | (379.07) % | ||||
| Revenue | 18.6 K | ||||
| EBITDA | (6.16 M) | ||||
| Net Income | (6.61 M) | ||||
| Cash And Equivalents | 723.48 K | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 1.04 M | ||||
| Current Ratio | 0.59 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Heart Stock Analysis
When running Heart Test's price analysis, check to measure Heart Test's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heart Test is operating at the current time. Most of Heart Test's value examination focuses on studying past and present price action to predict the probability of Heart Test's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Heart Test's price. Additionally, you may evaluate how the addition of Heart Test to your portfolios can decrease your overall portfolio volatility.